Skip to main content
OpenTrials
Completed

NCT Number: NCT05136560

Safety and Efficacy of Early Administration of Dexamethasone in High-risk Sepsis

The purpose of this study is to investigate the safety and efficacy of early administration of two different doses of dexamethasone in high risk septic patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Bundang CHA hospital, Seongnam-si, Gyeonggi-do, South Korea

Loading trial locations.

About this study

The septic adult patients of high risk would be enrolled in 2 emergency departments.

Sepsis would be defined by Sepsis-3 definition. High risk is defined as initial systolic blood pressure less than 90 mmHg or blood lactate level over 2 mmol/L.

The enrolled patients would be randomized to 3 groups: control, low dose dexamethasone (0.1 mg/kg iv), and high dose dexamethasone (0.2mg/kg iv).

The study drug is blinded and administered after enrollment for 2 days. Sample size would be 102, considering 10% of drop-out rate, allocating 30 patients to each groups.

Efficacy would be evaluated as follows; 28 day and 90 day mortality, time to septic shock, time to shock reversal, administration of steroid according to guideline, ventilator free days, Continuous renal replacement, Length of stay in ICU or hospital, delta SOFA score on day 3 and day 7,

Safety would be evaluated as follows; Superinfection Gastrointestinal bleeding, Hyperglycemia, Hypernatremia

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sepsis defined by Sepsis-3 definition
  • Initial systolic blood pressure < 90mmHg or blood lactate level >2mmol/L

Exclusion criteria

  • advanced directive for "Do not resuscitation"
  • recent systemic administration of glucocorticoid (4 weeks)
  • recent systemic administration of chemotherapy (4 weeks)
  • recent systemic administration of immunosuppressant (4 weeks)
  • expected life less than 90 days
  • Transferred from other hospital
  • Sepsis diagnosed 24 hours after ED admission
  • Use of etomidate in ED
  • pregnant or on lactation
  • no informed consent

Treatment and study plan

Dexamethasone

Drug

Intervention drugs would be administered for 1 or 2 days.

Other names: JEIL Dexamethasone Injection

Primary outcomes

  1. 28 day mortality

    Time frame: 28 days

    death at 28 day

Secondary outcomes

  1. 90 day mortality

    Time frame: 90 days

    death at 90 day

  2. Time to septic shock

    Time frame: up to 1 month, During hospital stay

    Time to septic shock after enrollment

  3. Time to shock reversal

    Time frame: up to 1 month, During hospital stay

    time required for shock reversal

  4. Administration of steroid according to guideline, yes or no

    Time frame: up to 1 month, During hospital stay

    Need for additional steroid requirement according to the sepsis guideline

  5. ventilator free days

    Time frame: up to 3 month, During hospital stay

    days independent from ventilator care

  6. continuous renal replacement therapy (CRRT)

    Time frame: up to 3 month, During hospital stay

    requirement of CRRT

  7. Length of stay in intensive care unit (ICU)

    Time frame: up to 6 month, During hospital stay

    Days spent in intensive care unit (ICU)

  8. Length of stay in hospital

    Time frame: up to 6 month, During hospital stay

    Days spent in hospital

  9. Delta SOFA sore on day 3 and 7

    Time frame: 7 days

    Change of SOFA score on day 3 and day 7

  10. Superinfection

    Time frame: 28 days

    secondary infection

  11. Gastrointestinal bleeding

    Time frame: 14 days

    Gastrointestinal bleeding at any amount

  12. Hyperglycemia

    Time frame: 7 days

    serum glucose >150 mg/dL

  13. Hypernatremia

    Time frame: 7 days

    serum sodium >150mmol/L

Sponsors and collaborators

Lead sponsor

CHA University

Other

Registry information

Official study title

A Randomized, Double-blind, Multi-center Clinical Trial to Evaluate the Safety and Efficacy of Early Administration of Dexamethasone in High-risk Sepsis

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Nov 29, 2021
Registry last updated
Jun 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.